.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Baxter
Teva
QuintilesIMS
UBS
Cantor Fitzgerald
Chinese Patent Office
Julphar
Express Scripts
Novartis

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,358,352

« Back to Dashboard

Which drugs does patent 9,358,352 protect, and when does it expire?


Patent 9,358,352 protects AFREZZA and is included in one NDA.

This patent has two hundred and thirty-four patent family members in twenty-three countries.

Summary for Patent: 9,358,352

Title:Dry powder drug delivery system and methods
Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, endocrine disease such as diabetes and/or obesity.
Inventor(s): Smutney; Chad C. (Watertown, CT), Adamo; Benoit (Mount Kisco, NY), Polidoro; John M. (Coventry, CT), Kinsey; P. Spencer (Sandy Hook, CT), Overfield; Dennis (Fairfield, CT), Sahi; Carl (Coventry, CT), Billings; Christine (Danbury, CT), Marino; Mark T. (Danbury, CT)
Assignee: MannKind Corporation (Valencia, CA)
Application Number:13/702,024
Patent Claim Types:
see list of patent claims
Delivery; Formulation; Compound; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-001Jun 27, 2014RXYesNo► Subscribe► Subscribe► SubscribeYUSE OF AN INHALER TO ADMINISTER DRY POWDER MEDICAMENT
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-002Jun 27, 2014RXYesYes► Subscribe► Subscribe► SubscribeYUSE OF AN INHALER TO ADMINISTER DRY POWDER MEDICAMENT
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-003Apr 17, 2015RXYesNo► Subscribe► Subscribe► SubscribeYUSE OF AN INHALER TO ADMINISTER DRY POWDER MEDICAMENT
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 9,358,352

PCT Information
PCT FiledJune 21, 2011PCT Application Number:PCT/US2011/041303
PCT Publication Date:December 29, 2011PCT Publication Number: WO2011/163272

Non-Orange Book Patents for Patent: 9,358,352

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,339,615Dry powder inhaler and system for drug delivery► Subscribe
9,192,675Dry powder inhaler and system for drug delivery► Subscribe
8,485,180Dry powder drug delivery system► Subscribe
9,446,001Increasing drug affinity for crystalline microparticle surfaces► Subscribe
9,078,866Method for treating hyperglycemia with GLP-1► Subscribe
8,912,193Dry powder inhaler and system for drug delivery► Subscribe
7,799,344Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents► Subscribe
9,511,198Dry powder inhaler and system for drug delivery► Subscribe
9,717,689Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents► Subscribe
8,499,757Dry powder inhaler and system for drug delivery► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,358,352

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea20150070065► Subscribe
South Korea101655032► Subscribe
Russian Federation2013102529► Subscribe
Russian Federation2487731► Subscribe
Russian Federation2011140170► Subscribe
Russian Federation2474415► Subscribe
Russian Federation2010120666► Subscribe
Russian Federation2468832► Subscribe
Russian Federation2011100779► Subscribe
Germany202009018480► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Moodys
Fish and Richardson
Julphar
Argus Health
Cantor Fitzgerald
Deloitte
Covington
Cerilliant
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot